Savara Inc. (SVRA)
Savara Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Yardley, PA, US. The stock last traded at $5.75, up 3.23% on the session, giving a market capitalisation of $1.18B. On trailing twelve-month figures it carries a trailing P/E of -9.91, a net margin of 0.0%. Its beta of 0.26 implies it has historically moved less than the broad market.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Savara Inc. is most often compared with the following Healthcare names: